{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:34:45Z","timestamp":1791135285818,"version":"4.1.0"},"reference-count":286,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002608","name":"American Thyroid Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbcan.2025.189332","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:42:31Z","timestamp":1745376151000},"page":"189332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors"],"prefix":"10.1016","volume":"1880","author":[{"given":"Hannah M.","family":"Hylton-McComas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos V.","family":"Floros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne O.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189332_bb0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2025.189332_bb0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000481390","article-title":"Neuroendocrine neoplasms: dichotomy, origin and classifications","volume":"33","author":"Kloppel","year":"2017","journal-title":"Visc Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189332_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bbcan.2025.189332_bb0020","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihimaki","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-13-0539","article-title":"Smoking, p53 mutation, and lung cancer","volume":"12","author":"Gibbons","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0030","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 inhibition in small-cell lung Cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or Olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0040","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0045","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/j.1460-2075.1993.tb05742.x","article-title":"Interactions of the p107 and Rb proteins with E2F during the cell proliferation response","volume":"12","author":"Schwarz","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2025.189332_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.cr.7290031","article-title":"Regulation of the G1 phase of the mammalian cell cycle","volume":"10","author":"Donjerkovic","year":"2000","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0092-8674(91)90557-F","article-title":"The E2F transcription factor is a cellular target for the RB protein","volume":"65","author":"Chellappan","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0065","doi-asserted-by":"crossref","first-page":"12261","DOI":"10.1074\/jbc.271.21.12261","article-title":"The N-terminal region of E2F-1 is required for transcriptional activation of a new class of target promoter","volume":"271","author":"Shin","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb0070","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1101\/gr.6783507","article-title":"A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members","volume":"17","author":"Xu","year":"2007","journal-title":"Genome Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1023\/A:1025586207239","article-title":"The role of the transcription factor DP in apoptosis","volume":"8","author":"Hitchens","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbcan.2025.189332_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0959-437X(98)80058-0","article-title":"Regulation of cell proliferation by the E2F transcription factors","volume":"8","author":"Helin","year":"1998","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4161\/cc.2.4.428","article-title":"E2F1 and c-Myc in cell growth and death","volume":"2","author":"Matsumura","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2025.189332_bb0090","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1101\/gad.12.15.2245","article-title":"The regulation of E2F by pRB-family proteins","volume":"12","author":"Dyson","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0095","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1101\/gad.813200","article-title":"The Rb\/E2F pathway: expanding roles and emerging paradigms","volume":"14","author":"Harbour","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1101\/gad.7.3.331","article-title":"Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4","volume":"7","author":"Kato","year":"1993","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(92)90360-O","article-title":"Identification and properties of an atypical catalytic subunit (p34PSK-J3\/cdk4) for mammalian D type G1 cyclins","volume":"71","author":"Matsushime","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187667","article-title":"Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma","volume":"12","author":"Ali","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189332_bb0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tlcr.2017.10.07","article-title":"Transcriptional deregulation underlying the pathogenesis of small cell lung cancer","volume":"7","author":"Kim","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0120","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0125","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2025.189332_bb0130","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/sj.bjc.6603167","article-title":"Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer","volume":"94","author":"Coe","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071670","article-title":"Genomic deregulation of the E2F\/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer","volume":"8","author":"Coe","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189332_bb0140","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/sj.onc.1204242","article-title":"Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma","volume":"20","author":"Eymin","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.07.005","article-title":"Nuclear overexpression of the E2F3 transcription factor in human lung cancer","volume":"54","author":"Cooper","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0150","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/endrev\/bnad006","article-title":"Advances in the treatment of Gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?","volume":"44","author":"Garcia-Carbonero","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.604341","article-title":"Clinical epigenetics of neuroendocrine tumors: the road ahead","volume":"11","author":"Colao","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bbcan.2025.189332_bb0160","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1634\/theoncologist.2008-0259","article-title":"Neuroendocrine tumors of the pancreas","volume":"14","author":"Ehehalt","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2025.189332_bb0165","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41591-019-0493-4","article-title":"Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors","volume":"25","author":"Cejas","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gcc.1180","article-title":"Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL","volume":"32","author":"Moore","year":"2001","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.devcel.2004.11.008","article-title":"The role of GDNF\/ret signaling in ureteric bud cell fate and branching morphogenesis","volume":"8","author":"Shakya","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-1838(97)00002-7","article-title":"RET proto-oncogene is important for the development of respiratory CO2 sensitivity","volume":"63","author":"Burton","year":"1997","journal-title":"J. Auton. Nerv. Syst."},{"key":"10.1016\/j.bbcan.2025.189332_bb0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-006-0263-4","article-title":"RET and neuroendocrine tumors","volume":"9","author":"Murakumo","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.bbcan.2025.189332_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41389-021-00372-5","article-title":"Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors","volume":"10","author":"Carter","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbcan.2025.189332_bb0195","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<668::AID-CNCR4>3.0.CO;2-J","article-title":"Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis","volume":"80","author":"Wang","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0200","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1759-7714.14804","article-title":"Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung","volume":"14","author":"Oshima","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0205","doi-asserted-by":"crossref","first-page":"17034","DOI":"10.1073\/pnas.1207310109","article-title":"A framework for identification of actionable cancer genome dependencies in small cell lung cancer","volume":"109","author":"Sos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0210","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung Cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0215","first-page":"1708","article-title":"Myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens","volume":"51","author":"Brennan","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0220","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1172\/JCI112999","article-title":"Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course","volume":"79","author":"Johnson","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189332_bb0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0230","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0235","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/15384101.2017.1339849","article-title":"Family matters: how MYC family oncogenes impact small cell lung cancer","volume":"16","author":"Bragelmann","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2025.189332_bb0240","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fonc.2020.00741","article-title":"Targeted therapies and biomarkers in small cell lung Cancer","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0245","series-title":"The Molecular Basis of Cancer","author":"De Beradinis","year":"2008"},{"key":"10.1016\/j.bbcan.2025.189332_bb0250","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1038\/onc.2008.55","article-title":"A role for Myc in facilitating transcription activation by E2F1","volume":"27","author":"Leung","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0255","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0260","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.ge.20.120186.002045","article-title":"The myc oncogene: its role in transformation and differentiation","volume":"20","author":"Cole","year":"1986","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.bbcan.2025.189332_bb0265","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/jvi.42.3.773-779.1982","article-title":"Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29","volume":"42","author":"Vennstrom","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0270","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1096\/fasebj.12.9.633","article-title":"The molecular role of Myc in growth and transformation: recent discoveries lead to new insights","volume":"12","author":"Facchini","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2025.189332_bb0275","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014191","article-title":"Genome recognition by MYC","volume":"4","author":"Sabo","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0280","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/sj.onc.1201280","article-title":"Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E\/CDK2 kinase activity","volume":"15","author":"Berns","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0285","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1073\/pnas.082005599","article-title":"Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes","volume":"99","author":"Menssen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0290","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.2006410","article-title":"Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc","volume":"251","author":"Blackwood","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189332_bb0295","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1038\/sj.onc.1202748","article-title":"The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation","volume":"18","author":"Cole","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tcb.2014.10.006","article-title":"Taming of the beast: shaping Myc-dependent amplification","volume":"25","author":"Wolf","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0305","first-page":"73","article-title":"Metabolism in Cancer","author":"Schmitt","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.bbcan.2025.189332_bb0310","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0315","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0320","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0325","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1101\/gr.276313.121","article-title":"MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites","volume":"32","author":"See","year":"2022","journal-title":"Genome Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0330","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","article-title":"Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism","volume":"23","author":"Schuijers","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189332_bb0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/35106593","article-title":"The E2F1-3 transcription factors are essential for cellular proliferation","volume":"414","author":"Wu","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0340","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1101\/gad.949802","article-title":"E2F integrates cell cycle progression with DNA repair, replication, and G(2)\/M checkpoints","volume":"16","author":"Ren","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0345","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/ncb3210","article-title":"Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles","volume":"17","author":"Liu","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0355","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc2274","article-title":"The interplay between MYC and HIF in cancer","volume":"8","author":"Dang","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0360","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1073\/pnas.0604129103","article-title":"Global mapping of c-Myc binding sites and target gene networks in human B cells","volume":"103","author":"Zeller","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0365","doi-asserted-by":"crossref","first-page":"21797","DOI":"10.1074\/jbc.C000023200","article-title":"Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc","volume":"275","author":"Osthus","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb0370","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/MCB.24.13.5923-5936.2004","article-title":"Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays","volume":"24","author":"Kim","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0375","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189332_bb0380","doi-asserted-by":"crossref","first-page":"32529","DOI":"10.1074\/jbc.271.51.32529","article-title":"Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase a gene promoters contain essential binding sites for hypoxia-inducible factor 1","volume":"271","author":"Semenza","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb0385","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1128\/MCB.21.10.3436-3444.2001","article-title":"Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells","volume":"21","author":"Seagroves","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0390","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/geno.1998.5416","article-title":"The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation","volume":"52","author":"Iyer","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.bbcan.2025.189332_bb0395","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ccell.2014.11.024","article-title":"Deregulated Myc requires MondoA\/mlx for metabolic reprogramming and tumorigenesis","volume":"27","author":"Carroll","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0400","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1083\/jcb.200703099","article-title":"Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells","volume":"178","author":"Yuneva","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0405","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0410","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"C-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0415","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189332_bb0420","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0425","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189332_bb0430","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","article-title":"Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis","volume":"25","author":"Li","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0435","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2007.04.001","article-title":"HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity","volume":"11","author":"Zhang","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002722","article-title":"Global regulation of nucleotide biosynthetic genes by c-Myc","volume":"3","author":"Liu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189332_bb0445","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.4161\/cc.6390","article-title":"Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells","volume":"7","author":"Mannava","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2025.189332_bb0450","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1128\/MCB.15.5.2527","article-title":"An E-box-mediated increase in cad transcription at the G1\/S-phase boundary is suppressed by inhibitory c-Myc mutants","volume":"15","author":"Miltenberger","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0455","doi-asserted-by":"crossref","first-page":"36267","DOI":"10.1074\/jbc.M110.141606","article-title":"Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry","volume":"285","author":"Morrish","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb0460","doi-asserted-by":"crossref","first-page":"10450","DOI":"10.1073\/pnas.1409778111","article-title":"Alteration of the lipid profile in lymphomas induced by MYC overexpression","volume":"111","author":"Eberlin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0465","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1101\/sqb.2011.76.011296","article-title":"Therapeutic targeting of Myc-reprogrammed cancer cell metabolism","volume":"76","author":"Dang","year":"2011","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0470","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrm3359","article-title":"Specialized ribosomes: a new frontier in gene regulation and organismal biology","volume":"13","author":"Xue","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0475","doi-asserted-by":"crossref","first-page":"pe38","DOI":"10.1126\/scisignal.2003477","article-title":"Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling","volume":"5","author":"Ruggero","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2025.189332_bb0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev.pharmtox.010909.105844","article-title":"The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer","volume":"50","author":"Drygin","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0485","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012336","article-title":"Translational control in cancer etiology","volume":"5","author":"Ruggero","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0490","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07449","article-title":"Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency","volume":"456","author":"Barna","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0495","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-09-1970","article-title":"The role of Myc-induced protein synthesis in cancer","volume":"69","author":"Ruggero","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0500","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nature01327","article-title":"Direct activation of RNA polymerase III transcription by c-Myc","volume":"421","author":"Gomez-Roman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ncb1225","article-title":"C-Myc associates with ribosomal DNA and activates RNA polymerase I transcription","volume":"7","author":"Arabi","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ncb1224","article-title":"C-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I","volume":"7","author":"Grandori","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0515","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1038\/sj.emboj.7600335","article-title":"MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation","volume":"23","author":"Poortinga","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2025.189332_bb0520","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1101\/gad.285504","article-title":"mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability","volume":"18","author":"Mayer","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017449","article-title":"MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors","volume":"6","author":"Clegg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189332_bb0530","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/cncr.26729","article-title":"Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy","volume":"118","author":"Zafarana","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0535","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/0008-5472.CAN-03-3176","article-title":"C-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism","volume":"64","author":"Knies-Bamforth","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0540","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1097-2765(00)80350-0","article-title":"Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion","volume":"3","author":"Pelengaris","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0545","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1038\/sj.onc.1203589","article-title":"Angiogenesis is an early event in the generation of myc-induced lymphomas","volume":"19","author":"Brandvold","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0550","first-page":"4596","article-title":"The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin a","volume":"60","author":"Breit","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0555","first-page":"201","article-title":"An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype","volume":"11","author":"Ngo","year":"2000","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.bbcan.2025.189332_bb0560","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1101\/gad.1024602","article-title":"C-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression","volume":"16","author":"Baudino","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0565","doi-asserted-by":"crossref","first-page":"30741","DOI":"10.1074\/jbc.271.48.30741","article-title":"Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene","volume":"271","author":"Tikhonenko","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb0570","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/nar\/28.11.2268","article-title":"Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA","volume":"28","author":"Janz","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \"undruggable\" MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2025.189332_bb0580","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/0008-5472.CAN-22-0232","article-title":"MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of Proinflammatory macrophages","volume":"83","author":"Dhanasekaran","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0585","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","article-title":"Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast Cancer","volume":"10","author":"Lee","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001388","article-title":"MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination","volume":"9","author":"Wu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0595","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0600","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3748\/wjg.v20.i10.2429","article-title":"Intratumoral functional heterogeneity and chemotherapy","volume":"20","author":"Sipos","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0605","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr3658","article-title":"Breast cancer intra-tumor heterogeneity","volume":"16","author":"Martelotto","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0610","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/2045-3701-4-69","article-title":"Evolving concepts of tumor heterogeneity","volume":"4","author":"Zellmer","year":"2014","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbcan.2025.189332_bb0615","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0620","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate Cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0625","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/onc.2010.10","article-title":"Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb0630","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate Cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0635","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41467-017-01967-6","article-title":"MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance","volume":"8","author":"Farrell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb0640","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0645","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/path.1065","article-title":"Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas","volume":"196","author":"Gugger","year":"2002","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0650","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0655","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/0008-5472.CAN-15-2906","article-title":"A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers","volume":"77","author":"Jung","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0660","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-22-0796","article-title":"Extrachromosomal DNA amplification contributes to small cell lung Cancer heterogeneity and is associated with worse outcomes","volume":"13","author":"Pongor","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081753","article-title":"Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189332_bb0670","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbcan.2025.189332_bb0675","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41416-021-01407-9","article-title":"Large cell neuroendocrine lung carcinoma: consensus statement from the British thoracic oncology group and the Association of Pulmonary Pathologists","volume":"125","author":"Lindsay","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0680","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.3747\/co.25.3808","article-title":"Advanced typical and atypical carcinoid tumours of the lung: management recommendations","volume":"25","author":"Melosky","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0685","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0690","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/cancers4030777","article-title":"Neuroendocrine tumors of the lung","volume":"4","author":"Fisseler-Eckhoff","year":"2012","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189332_bb0695","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/306194a0","article-title":"Amplification and expression of the c-myc oncogene in human lung cancer cell lines","volume":"306","author":"Little","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0700","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/318069a0","article-title":"L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer","volume":"318","author":"Nau","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0705","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1073\/pnas.83.4.1092","article-title":"Human small-cell lung cancers show amplification and expression of the N-myc gene","volume":"83","author":"Nau","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb0710","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jcb.240630516","article-title":"MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer","volume":"24","author":"Johnson","year":"1996","journal-title":"J. Cell. Biochem. Suppl."},{"key":"10.1016\/j.bbcan.2025.189332_bb0715","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.2838909","article-title":"Abnormalities in structure and expression of the human retinoblastoma gene in SCLC","volume":"241","author":"Harbour","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189332_bb0720","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.2554494","article-title":"p53: a frequent target for genetic abnormalities in lung cancer","volume":"246","author":"Takahashi","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189332_bb0725","first-page":"2683","article-title":"Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics","volume":"49","author":"Takahashi","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0730","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/319780a0","article-title":"Differential expression of myc family genes during murine development","volume":"319","author":"Zimmerman","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0735","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41467-019-11371-x","article-title":"MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer","volume":"10","author":"Dammert","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb0740","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Rudin","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2025.189332_bb0745","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","article-title":"Integrative analysis of a large real-world cohort of small cell lung Cancer identifies distinct genetic subtypes and insights into histologic transformation","volume":"13","author":"Sivakumar","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0750","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K","article-title":"Heterogenous amplification of myc family oncogenes in small cell lung carcinoma","volume":"66","author":"Noguchi","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0755","first-page":"5163","article-title":"Myc family DNA amplification in small cell lung cancer patients\u2019 tumors and corresponding cell lines","volume":"48","author":"Johnson","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0760","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","article-title":"Acquired cross-resistance in small cell lung Cancer due to extrachromosomal DNA amplification of MYC paralogs","volume":"14","author":"Pal Choudhuri","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0765","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb0770","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0165-4608(88)90187-2","article-title":"Cytogenetic abnormalities in human small cell lung carcinoma: cell lines characterized for myc gene amplification","volume":"30","author":"Waters","year":"1988","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbcan.2025.189332_bb0775","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/2159-8290.CD-13-0799","article-title":"MAX inactivation in small cell lung cancer disrupts MYC-SWI\/SNF programs and is synthetic lethal with BRG1","volume":"4","author":"Romero","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0780","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0785","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1101\/sqb.2005.70.026","article-title":"Genotype-phenotype relationships in a mouse model for human small-cell lung cancer","volume":"70","author":"Calbo","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0790","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cell.2014.02.031","article-title":"Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing","volume":"156","author":"McFadden","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0795","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1101\/gad.279307.116","article-title":"Genetic requirement for Mycl and efficacy of RNA pol I inhibition in mouse models of small cell lung cancer","volume":"30","author":"Kim","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0800","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/emmm.201303297","article-title":"Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells","volume":"6","author":"Huijbers","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0805","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1101\/gad.340133.120","article-title":"MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity","volume":"34","author":"Grunblatt","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0810","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/j.1460-2075.1991.tb07652.x","article-title":"A fusion protein formed by L-myc and a novel gene in SCLC","volume":"10","author":"Makela","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2025.189332_bb0815","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/2159-8290.CD-21-0441","article-title":"Rlf-Mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung Cancer","volume":"11","author":"Ciampricotti","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0820","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2023.11.022","article-title":"SCLC classification by platinum sensitivity in the era of immunotherapy: mere relic or a valuable treasure to keep?","volume":"19","author":"Owonikoko","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0825","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0830","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","article-title":"Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer","volume":"68","author":"Hann","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0835","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0840","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2159-8290.CD-17-0935","article-title":"Genomic and functional Fidelity of small cell lung Cancer patient-derived xenografts","volume":"8","author":"Drapkin","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0845","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination Olaparib and Temozolomide in relapsed small-cell lung Cancer","volume":"9","author":"Farago","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0850","first-page":"2913","article-title":"Establishment and identification of small cell lung cancer cell lines having classic and variant features","volume":"45","author":"Carney","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0855","first-page":"2924","article-title":"Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties","volume":"45","author":"Gazdar","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0860","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","article-title":"ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs","volume":"16","author":"Borromeo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189332_bb0865","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0870","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1172\/JCI112604","article-title":"Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene","volume":"78","author":"Johnson","year":"1986","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189332_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung Cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb0880","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2578","article-title":"Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer","volume":"7","author":"Patel","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2025.189332_bb0885","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-18-4140","article-title":"MYC-driven small-cell lung Cancer is metabolically distinct and vulnerable to arginine depletion","volume":"25","author":"Chalishazar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0890","article-title":"Aurora a kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1","volume":"4","author":"Li","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0895","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora a kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0900","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","article-title":"Cells lacking the RB1 tumor suppressor gene are Hyperdependent on Aurora B kinase for survival","volume":"9","author":"Oser","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0905","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1158\/1535-7163.MCT-16-0298","article-title":"Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo","volume":"15","author":"Helfrich","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb0910","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0915","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","article-title":"Aurora kinases a and B are up-regulated by Myc and are essential for maintenance of the malignant state","volume":"116","author":"den Hollander","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189332_bb0920","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-16-0355","article-title":"Genomic profiling of large-cell neuroendocrine carcinoma of the lung","volume":"23","author":"Miyoshi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb0925","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","article-title":"Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors","volume":"9","author":"George","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb0930","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb0935","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41467-019-11276-9","article-title":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids","volume":"10","author":"Alcala","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb0940","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1210\/jc.2013-2782","article-title":"MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids","volume":"99","author":"Swarts","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189332_bb0945","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3892\/or.2012.2017","article-title":"Phosphatidylinositol-3-kinase alpha catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours","volume":"28","author":"Capodanno","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2025.189332_bb0950","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014407","article-title":"MYC and the control of apoptosis","volume":"4","author":"McMahon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb0955","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1126\/science.8091232","article-title":"Mediation of c-Myc-induced apoptosis by p53","volume":"265","author":"Hermeking","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189332_bb0960","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1101\/gad.8.23.2817","article-title":"Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1\/cip1","volume":"8","author":"Wagner","year":"1994","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189332_bb0965","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122828","article-title":"Enhancer of Zeste homolog 2 (EZH2) is a marker of high-grade neuroendocrine neoplasia in Gastroenteropancreatic and pulmonary tract and predicts poor prognosis","volume":"14","author":"Bremer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189332_bb0980","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/cas.14717","article-title":"C-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation","volume":"112","author":"Chang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2025.189332_bb0985","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejso.2014.06.004","article-title":"Pancreatic neuroendocrine tumor: a multivariate analysis of factors influencing survival","volume":"40","author":"Birnbaum","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb0990","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<326::AID-CNCR9>3.0.CO;2-O","article-title":"Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status","volume":"85","author":"Berger","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb0995","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1000","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1078-1439(97)00039-2","article-title":"Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium","volume":"3","author":"Shen","year":"1997","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1005","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb1010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular Tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/his.13856","article-title":"Primary renal well-differentiated neuroendocrine tumour (carcinoid): next-generation sequencing study of 11 cases","volume":"75","author":"Pivovarcikova","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.bbcan.2025.189332_bb1020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12022-008-9054-y","article-title":"Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature","volume":"20","author":"La Rosa","year":"2009","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mpo.2950200202","article-title":"Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome","volume":"20","author":"Remick","year":"1992","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","article-title":"Neuroendocrine tumors of genitourinary tract: recent advances","volume":"42","author":"Shehabeldin","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1746-1596-7-126","article-title":"Primary micro neuroendocrine tumor arising in a horseshoe kidney with cyst: report of a case and review of literature","volume":"7","author":"Zhang","year":"2012","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00428-023-03596-5","article-title":"Renal neuroendocrine tumors: clinical and molecular pathology with an emphasis on frequent association with ectopic Cushing syndrome","volume":"483","author":"Kasajima","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbcan.2025.189332_bb1045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb1050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb1055","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1158\/0008-5472.CAN-05-2769","article-title":"Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma","volume":"66","author":"Chesler","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1060","first-page":"2265","article-title":"N-Myc induces the tumor progression of prostate cancer by regulating FSCN1","volume":"44","author":"He","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2025.189332_bb1065","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/1078-0432.CCR-19-0317","article-title":"PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate Cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","article-title":"N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway","volume":"18","author":"Yin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb1075","first-page":"297","article-title":"Neuroblastoma","volume":"58","author":"Colon","year":"2011","journal-title":"Adv. Pediatr. Infect. Dis."},{"key":"10.1016\/j.bbcan.2025.189332_bb1080","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7394268","article-title":"Neuroblastoma origin and therapeutic targets for immunotherapy","volume":"2018","author":"Kholodenko","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.bbcan.2025.189332_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020338","article-title":"17q gain in neuroblastoma: a review of clinical and biological implications","volume":"16","author":"Mlakar","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189332_bb1090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/305245a0","article-title":"Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour","volume":"305","author":"Schwab","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb1095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb1100","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-20-3108","article-title":"Drugging the \u201cUndruggable\u201d MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers","volume":"81","author":"Wolpaw","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1105","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/acsmedchemlett.3c00274","article-title":"Kinases controlling stability of the oncogenic MYCN protein","volume":"14","author":"Smith","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2025.189332_bb1110","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.1073\/pnas.1610626113","article-title":"Structural basis of N-Myc binding by Aurora-a and its destabilization by kinase inhibitors","volume":"113","author":"Richards","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb1115","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-18-1381","article-title":"Phase II trial of alisertib in combination with irinotecan and Temozolomide for patients with relapsed or refractory neuroblastoma","volume":"24","author":"DuBois","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115033","article-title":"Targeted AURKA degradation: towards new therapeutic agents for neuroblastoma","volume":"247","author":"Rishfi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189332_bb1125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccell.2016.01.002","article-title":"Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination","volume":"29","author":"Ham","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3835(03)00101-0","article-title":"The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis","volume":"197","author":"van Noesel","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189332_bb1135","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","article-title":"Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma","volume":"20","author":"Dalton","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb1140","doi-asserted-by":"crossref","first-page":"27946","DOI":"10.18632\/oncotarget.8547","article-title":"High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition","volume":"7","author":"Bate-Eya","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189332_bb1145","doi-asserted-by":"crossref","first-page":"19295","DOI":"10.1038\/s41598-023-44993-9","article-title":"Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series","volume":"13","author":"De Ioris","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189332_bb1150","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1155","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189332_bb1160","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration Ibrutinib plus Venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1165","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189332_bb1170","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1175","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1878-0261.13649","article-title":"A guide to ferroptosis in cancer","volume":"18","author":"Yapici","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1180","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/0008-5472.CAN-20-1641","article-title":"MYCN-amplified neuroblastoma is addicted to Iron and vulnerable to inhibition of the system xc\u2212\/glutathione Axis","volume":"81","author":"Floros","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.15698\/cst2022.02.264","article-title":"MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma","volume":"6","author":"Floros","year":"2022","journal-title":"Cell Stress"},{"key":"10.1016\/j.bbcan.2025.189332_bb1190","first-page":"471","article-title":"MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis","volume":"3","author":"Alborzinia","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2025.189332_bb1195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41419-021-03790-w","article-title":"MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma","volume":"12","author":"Lu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189332_bb1200","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb1205","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1210","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2025.189332_bb1215","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1210\/jcem.82.6.4008","article-title":"Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC","volume":"82","author":"Wang","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189332_bb1220","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb1225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","article-title":"Alternative approaches to target Myc for cancer treatment","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb1230","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc904","article-title":"c-MYC: more than just a matter of life and death","volume":"2","author":"Pelengaris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb1235","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1021\/jacs.2c12732","article-title":"Demystifying the Druggability of the MYC family of oncogenes","volume":"145","author":"Karadkhelkar","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbcan.2025.189332_bb1240","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202103090","article-title":"The long journey to bring a Myc inhibitor to the clinic","volume":"220","author":"Whitfield","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nature07260","article-title":"Modelling Myc inhibition as a cancer therapy","volume":"455","author":"Soucek","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189332_bb1250","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0092-8674(82)90159-3","article-title":"Nuclear location of the putative transforming protein of avian myelocytomatosis virus","volume":"29","author":"Abrams","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1260","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-018-03900-x","article-title":"Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy","volume":"9","author":"Anker","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189332_bb1265","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","article-title":"Design and properties of a Myc derivative that efficiently homodimerizes","volume":"17","author":"Soucek","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb1270","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00248-19","article-title":"Omomyc reveals new mechanisms to inhibit the MYC oncogene","volume":"39","author":"Demma","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5012","article-title":"Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy","volume":"11","author":"Beaulieu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb1280","doi-asserted-by":"crossref","first-page":"31014","DOI":"10.18632\/oncotarget.8826","article-title":"Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation","volume":"7","author":"Fiorentino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189332_bb1285","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189332_bb1290","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189332_bb1295","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neo.2019.10.003","article-title":"Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells","volume":"21","author":"Otto","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2025.189332_bb1300","doi-asserted-by":"crossref","first-page":"77378","DOI":"10.18632\/oncotarget.12671","article-title":"MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells","volume":"7","author":"Kato","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189332_bb1305","article-title":"Safety and efficacy of Bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189332_bb1310","article-title":"First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI)","volume":"38","author":"Petrylak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1315","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the Management of Prostate Cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2025.189332_bb1320","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb1325","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574525","article-title":"PROTAC Bromodomain inhibitor ARV-825 displays anti-tumor activity in neuroblastoma by repressing expression of MYCN or c-Myc","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189332_bb1330","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1335","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb1340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora a in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccr.2008.12.008","article-title":"Unholy matrimony: Aurora a and N-Myc as malignant partners in neuroblastoma","volume":"15","author":"Maris","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1350","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1535-7163.MCT-23-0602","article-title":"Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with Everolimus","volume":"23","author":"Chang","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189332_bb1355","doi-asserted-by":"crossref","first-page":"E11894","DOI":"10.1073\/pnas.1811158115","article-title":"Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states","volume":"115","author":"Lake","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189332_bb1360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate Cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1365","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1370","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1375","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41388-024-02939-z","article-title":"Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer","volume":"43","author":"Chao","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189332_bb1380","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells","volume":"17","author":"Hoglund","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1385","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/0008-5472.CAN-12-1408","article-title":"MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells","volume":"73","author":"Wang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1390","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189332_bb1395","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2025.189332_bb1400","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1405","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189332_bb1410","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","article-title":"Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate Cancer","volume":"7","author":"Zou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189332_bb1415","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1420","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189332_bb1425","article-title":"MYCN function in neuroblastoma development","volume":"10","author":"Otte","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189332_bb1430","doi-asserted-by":"crossref","first-page":"38591","DOI":"10.18632\/oncotarget.5774","article-title":"MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:22:41Z","timestamp":1778214161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":286,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0304419X25000745"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189332","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189332"}}